TY  - CONF

T1  - PRO15 COST-EFFECTIVENESS OF NUSINERSEN AND ONASEMNOGENE ABEPARVOVEC FOR INFANTILE-ONSET SPINAL MUSCULAR ATROPHY (TYPE I SMA) IN THE US

JO  - Value in Health

PY  - 2019/05/09

AU  - Thokala P

AU  - Stevenson M

AU  - Kumar VM

AU  - Ren S

AU  - Chapman R

AU  - Ellis A

AU  - Rind D

ED  - 

DO  - DOI: 10.1016/j.jval.2019.04.1648

PB  - Elsevier BV

VL  - 22

SP  - S337

EP  - S338

Y2  - 2024/12/22

ER  -